Evaluation of a commercial SARS-CoV-2 multiplex PCR genotyping assay for variant identification in resource-scarce settings

• Published in: PloS one 2022-06, Vol.17 (6), p.e0269071-e0269071
• Main Authors: Umunnakwe, Chijioke N, Makatini, Zinhle N, Maphanga, Mathapelo, Mdunyelwa, Anele, Mlambo, Khamusi M, Manyaka, Puseletso, Nijhuis, Monique, Wensing, Annemarie, Tempelman, Hugo A
• Format: Article
• Language: English
• Subjects: Analysis; Assaying; Biology and life sciences; Coronaviruses; COVID-19; COVID-19 - diagnosis; DNA sequencing; Evaluation; Gene sequencing; Genotype; Genotyping; Humans; Laboratories; Medicine and health sciences; Multiplex Polymerase Chain Reaction; Multiplexing; Mutation; Nucleotide sequencing; Polymerase chain reaction; Real time; Reproducibility of Results; Research and Analysis Methods; Retrospective Studies; SARS-CoV-2 - genetics; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Surveillance; Whole genome sequencing
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0269071

The rapid emergence and spread of numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants across the globe underscores the crucial need for continuous SARS-CoV-2 surveillance to ensure that potentially more pathogenic variants are detected early and contained. Whole genome sequencing (WGS) is currently the gold standard for COVID-19 surveillance; however, it remains cost-prohibitive and requires specialized technical skills. To increase surveillance capacity, especially in resource-scarce settings, supplementary methods that are cost- and time-effective are needed. Real-time multiplex PCR genotyping assays offer an economical and fast solution for screening circulating and emerging variants while simultaneously complementing existing WGS approaches. In this study we evaluated the AllplexTM SARS-CoV-2 Variants II multiplex real-time PCR genotyping assay, Seegene (South Korea), and implemented it in retrospectively characterizing circulating SARS-CoV-2 variants in a rural South African setting between April and October 2021, prior to the emergence of the Omicron variant in South Africa. The AllplexTM SARS-CoV-2 Variants II real-time PCR assay demonstrated perfect concordance with whole-genome sequencing in detecting Beta and Delta variants and exhibited high specificity, sensitivity and reproducibility. Implementation of the assay in characterization of SARS-CoV-2 variants between April and October 2021 in a rural South African setting revealed a rapid shift from the Beta to the Delta variant between April and June. All specimens successfully genotyped in April were Beta variants and the Delta variant was not detected until May. By June, 78% of samples genotyped were Delta variants and in July >95% of all genotyped samples were Delta variants. The Delta variant continued to predominate through to the end of our analysis in October 2021. Taken together, a commercial SARS-CoV-2 variant genotyping assay detected the rapid rate at which the Delta variant displaced the Beta variant in Limpopo, an under-monitored province in South Africa. Such assays provide a quick and cost-effective method of monitoring circulating variants and should be used to complement genomic sequencing for COVID-19 surveillance especially in resource-scarce settings.